Amanda Przespolewski

1.1k total citations
37 papers, 212 citations indexed

About

Amanda Przespolewski is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Amanda Przespolewski has authored 37 papers receiving a total of 212 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 12 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Amanda Przespolewski's work include Acute Myeloid Leukemia Research (27 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Amanda Przespolewski is often cited by papers focused on Acute Myeloid Leukemia Research (27 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Amanda Przespolewski collaborates with scholars based in United States, Israel and Germany. Amanda Przespolewski's co-authors include Eunice S. Wang, Elizabeth A. Griffiths, Jeffrey Baron, Amro Elshoury, Swapna Thota, Yasmin Abaza, Michael Byrne, Abraham Fong, Feng Jin and Tae Hee Kim and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Amanda Przespolewski

35 papers receiving 210 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amanda Przespolewski United States 7 129 112 60 42 31 37 212
Peter Tan Australia 10 126 1.0× 109 1.0× 55 0.9× 85 2.0× 33 1.1× 18 252
Christos Demosthenous Greece 8 77 0.6× 71 0.6× 61 1.0× 47 1.1× 64 2.1× 19 202
Londa Fuller United States 5 203 1.6× 269 2.4× 69 1.1× 36 0.9× 46 1.5× 7 339
Jana Mihályová Czechia 7 84 0.7× 90 0.8× 136 2.3× 71 1.7× 49 1.6× 16 251
Giuseppina Uccello Italy 8 67 0.5× 65 0.6× 42 0.7× 31 0.7× 37 1.2× 12 125
Vadim Doronin Russia 7 155 1.2× 134 1.2× 82 1.4× 14 0.3× 40 1.3× 19 218
Lauren Harvey United States 6 112 0.9× 88 0.8× 179 3.0× 45 1.1× 20 0.6× 8 258
Wilbert B. Copeland United States 5 100 0.8× 159 1.4× 61 1.0× 52 1.2× 24 0.8× 8 249
Veronica Guerra United States 7 123 1.0× 117 1.0× 53 0.9× 13 0.3× 36 1.2× 15 214
Amanda R. Leonti United States 8 113 0.9× 99 0.9× 55 0.9× 35 0.8× 36 1.2× 32 193

Countries citing papers authored by Amanda Przespolewski

Since Specialization
Citations

This map shows the geographic impact of Amanda Przespolewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Przespolewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Przespolewski more than expected).

Fields of papers citing papers by Amanda Przespolewski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Przespolewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Przespolewski. The network helps show where Amanda Przespolewski may publish in the future.

Co-authorship network of co-authors of Amanda Przespolewski

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Przespolewski. A scholar is included among the top collaborators of Amanda Przespolewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Przespolewski. Amanda Przespolewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Przespolewski, Amanda, et al.. (2024). Updates in novel immunotherapeutic strategies for relapsed/refractory AML. Frontiers in Oncology. 14. 1374963–1374963. 5 indexed citations
2.
Awada, Hassan, Elizabeth A. Griffiths, James E. Thompson, et al.. (2023). Outcomes of Extramedullary Acute Myeloid Leukemia with Gemtuzumab Ozogamicin: Real-World Experience. Blood. 142(Supplement 1). 5916–5916. 1 indexed citations
3.
4.
Kim, Tae Hee, et al.. (2022). Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia. Frontiers in Oncology. 12. 826768–826768. 5 indexed citations
5.
Singh, Abhay, Nuria Mencia-Trinchant, Elizabeth A. Griffiths, et al.. (2021). DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors. Blood. 138(Supplement 1). 4295–4295. 4 indexed citations
6.
Singh, Abhay, Megan M. Herr, Elizabeth A. Griffiths, et al.. (2021). Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. Scientific Reports. 11(1). 23284–23284. 4 indexed citations
7.
Singh, Abhay, Swapna Thota, Terrence Bradley, et al.. (2021). Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone. Clinical Lymphoma Myeloma & Leukemia. 21(9). 613–620. 1 indexed citations
8.
Altman, Jessica K., Bhavana Bhatnagar, Sameem Abedin, et al.. (2021). Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3-Mutated AML: Results of a Phase 1 Study. Blood. 138(Supplement 1). 2343–2343. 4 indexed citations
9.
Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2020). Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research. 93. 106367–106367. 13 indexed citations
10.
Przespolewski, Amanda & Elizabeth A. Griffiths. (2020). BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting. Blood Reviews. 43. 100654–100654. 9 indexed citations
11.
Przespolewski, Amanda, Elizabeth A. Griffiths, James E. Thompson, et al.. (2020). Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 136(Supplement 1). 20–21. 3 indexed citations
12.
Singh, Abhay, Jeffrey Baron, Amanda Przespolewski, et al.. (2020). Predictors of vascular disease in myelodysplastic syndromes. SHILAP Revista de lepidopterología. 1(2). 467–472. 3 indexed citations
13.
Przespolewski, Amanda, et al.. (2020). PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. Blood Reviews. 45. 100696–100696. 15 indexed citations
14.
Chen, George L., Paul K. Wallace, Yali Zhang, et al.. (2020). Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(11). 2147–2154. 3 indexed citations
15.
Przespolewski, Amanda, Chetasi Talati, Salman Fazal, et al.. (2019). Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis.. Journal of Clinical Oncology. 37(15_suppl). e18530–e18530. 5 indexed citations
16.
Baron, Jeffrey, Han Yu, Amanda Przespolewski, et al.. (2019). Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study. Blood. 134(Supplement_1). 3501–3501. 1 indexed citations
17.
Elshoury, Amro, Amanda Przespolewski, Jeffrey Baron, & Eunice S. Wang. (2019). Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. Expert Review of Anticancer Therapy. 19(3). 273–286. 18 indexed citations
18.
Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2018). Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy. Blood. 132(Supplement 1). 665–665. 5 indexed citations
19.
Przespolewski, Amanda, et al.. (2018). Advances in Immunotherapy for Acute Myeloid Leukemia. Future Oncology. 14(10). 963–978. 35 indexed citations
20.
Przespolewski, Amanda & Eunice S. Wang. (2016). Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia. Expert Opinion on Investigational Drugs. 25(7). 771–780. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Tan Breakdown of academic impact, for papers by Christos Demosthenous Breakdown of academic impact, for papers by Londa Fuller Breakdown of academic impact, for papers by Jana Mihályová Breakdown of academic impact, for papers by Giuseppina Uccello Breakdown of academic impact, for papers by Vadim Doronin Breakdown of academic impact, for papers by Lauren Harvey Breakdown of academic impact, for papers by Wilbert B. Copeland Breakdown of academic impact, for papers by Veronica Guerra Breakdown of academic impact, for papers by Amanda R. Leonti
Rankless by CCL
2026